Scancell Holdings plc

DB:SCP Stock Report

Market Cap: €156.6m

Scancell Holdings Valuation

Is SCP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SCP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SCP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCP?

Key metric: As SCP is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SCP. This is calculated by dividing SCP's market cap by their current book value.
What is SCP's PB Ratio?
PB Ratio-37.1x
Book-UK£3.50m
Market CapUK£130.14m

Price to Book Ratio vs Peers

How does SCP's PB Ratio compare to its peers?

The above table shows the PB ratio for SCP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
HPHA Heidelberg Pharma
2.9x-33.0%€103.9m
FYB Formycon
1.4x31.5%€827.2m
2INV 2invest
1xn/a€63.8m
BIO3 Biotest
2x29.3%€1.4b
SCP Scancell Holdings
n/a-22.4%€130.1m

Price-To-Book vs Peers: SCP has negative equity and a Price-To-Book Ratio (-37.1x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does SCP's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
SCP is unprofitableIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: SCP has negative equity and a Price-To-Book Ratio (-37.1x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is SCP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-37.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SCP's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SCP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.14
€0.30
+113.3%
15.4%€0.36€0.25n/a3
Nov ’25€0.14
€0.30
+120.2%
15.4%€0.36€0.25n/a3
Oct ’25€0.14
€0.30
+105.0%
15.4%€0.36€0.25n/a3
Sep ’25€0.19
€0.29
+55.2%
15.4%€0.36€0.25n/a3
Aug ’25€0.16
€0.29
+83.1%
15.4%€0.36€0.25n/a3
Jul ’25€0.11
€0.29
+164.1%
15.6%€0.35€0.25n/a3
Jun ’25€0.097
€0.29
+199.8%
15.5%€0.35€0.25n/a3
May ’25€0.089
€0.29
+226.5%
15.5%€0.35€0.25n/a3
Apr ’25€0.10
€0.29
+190.6%
15.5%€0.35€0.25n/a3
Mar ’25€0.10
€0.31
+211.5%
12.8%€0.35€0.27n/a2
Feb ’25€0.12
€0.31
+170.8%
12.8%€0.35€0.27n/a2
Nov ’24€0.11
€0.31
+185.5%
12.8%€0.34€0.27€0.142
Oct ’24€0.17
€0.31
+75.6%
13.2%€0.35€0.27€0.142
Sep ’24€0.094
€0.31
+230.3%
12.8%€0.35€0.27€0.192
Aug ’24€0.09
€0.31
+243.1%
12.8%€0.35€0.27€0.162
Jul ’24€0.13
€0.31
+134.3%
12.8%€0.35€0.27€0.112
Jun ’24€0.16
€0.30
+86.4%
13.2%€0.34€0.26€0.0972
May ’24€0.15
€0.30
+100.1%
13.2%€0.34€0.26€0.0892
Apr ’24€0.15
€0.30
+104.9%
13.2%€0.34€0.26€0.102
Mar ’24€0.17
€0.30
+72.2%
13.2%€0.34€0.26€0.102
Feb ’24€0.21
€0.30
+42.2%
13.2%€0.34€0.26€0.122
Jan ’24€0.26
€0.28
+8.6%
5.7%€0.30€0.27€0.0892
Dec ’23€0.25
€0.28
+13.9%
5.7%€0.30€0.27€0.112
Nov ’23€0.18
€0.29
+58.6%
5.7%€0.30€0.27€0.112

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

7D

-1.8%

1Y

0.2%